

Paolo M Comoglio

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5772855/paolo-m-comoglio-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

286
papers

26,558
citations

86
h-index

157
g-index

294
ext. papers

28,511
ext. citations

10.9
avg, IF

6.76
L-index

#	Paper	IF	Citations
286	Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. <i>Cancer Cell</i> , 2003 , 3, 347-61	24.3	1111
285	Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. <i>Cell</i> , 1999 , 99, 71-80	56.2	916
284	A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. <i>Cell</i> , 1994 , 77, 261-71	56.2	907
283	MET signalling: principles and functions in development, organ regeneration and cancer. <i>Nature Reviews Molecular Cell Biology</i> , 2010 , 11, 834-48	48.7	884
282	A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. <i>Cancer Discovery</i> , 2011 , 1, 508-23	24.4	668
281	Drug development of MET inhibitors: targeting oncogene addiction and expedience. <i>Nature Reviews Drug Discovery</i> , 2008 , 7, 504-16	64.1	656
280	Scatter-factor and semaphorin receptors: cell signalling for invasive growth. <i>Nature Reviews Cancer</i> , 2002 , 2, 289-300	31.3	630
279	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 738-746	21.7	533
278	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. <i>Cancer Discovery</i> , 2013 , 3, 658-73	24.4	489
277	Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. <i>Nature</i> , 1998 , 391, 285-8	50.4	447
276	Invasive growth: a MET-driven genetic programme for cancer and stem cells. <i>Nature Reviews Cancer</i> , 2006 , 6, 637-45	31.3	440
275	Plexin A is a neuronal semaphorin receptor that controls axon guidance. <i>Cell</i> , 1998 , 95, 903-16	56.2	392
274	The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. <i>Nature</i> , 2002 , 416, 187-90	50.4	380
273	A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. <i>Cell</i> , 2001 , 107, 643-54	56.2	376
272	Unified nomenclature for the semaphorins/collapsins. Semaphorin Nomenclature Committee. <i>Cell</i> , 1999 , 97, 551-2	56.2	364
271	The semaphorin 4D receptor controls invasive growth by coupling with Met. <i>Nature Cell Biology</i> , 2002 , 4, 720-4	23.4	361
270	Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. <i>Experimental Cell Research</i> , 1985 , 159, 141-57	4.2	359

269	Signalling by semaphorin receptors: cell guidance and beyond. <i>Trends in Cell Biology</i> , 2000 , 10, 377-83	18.3	298
268	Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. <i>Molecular Cell</i> , 2005 , 20, 881-90	17.6	282
267	Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. <i>Cell</i> , 1996 , 87, 531-42	56.2	275
266	Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. <i>Journal of Cell Biology</i> , 1997 , 138, 423-34	7.3	273
265	The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. <i>International Journal of Cancer</i> , 1991 , 49, 323-8	7.5	269
264	Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 645-61	9.7	261
263	Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. <i>Cancer Cell</i> , 2004 , 6, 61-73	24.3	261
262	The Met tyrosine kinase receptor in development and cancer. <i>Cancer and Metastasis Reviews</i> , 2008 , 27, 85-94	9.6	257
261	Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , 2016 , 17, 1386-1395	21.7	251
260	The MET receptor tyrosine kinase in invasion and metastasis. <i>Journal of Cellular Physiology</i> , 2007 , 213, 316-25	7	217
259	Interactions between growth factor receptors and adhesion molecules: breaking the rules. <i>Current Opinion in Cell Biology</i> , 2003 , 15, 565-71	9	215
258	The MET oncogene drives a genetic programme linking cancer to haemostasis. <i>Nature</i> , 2005 , 434, 396-400	30.4	206
257	Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. <i>Journal of Biological Chemistry</i> , 1995 , 270, 603-11	5.4	201
256	A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 11574-8	11.5	201
255	Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. <i>Journal of Experimental Medicine</i> , 2008 , 205, 1673-85	16.6	200
254	Cancer therapy: can the challenge be MET?. <i>Trends in Molecular Medicine</i> , 2005 , 11, 284-92	11.5	200
253	Overexpression of the Met/HGF receptor in ovarian cancer. <i>International Journal of Cancer</i> , 1994 , 58, 658-62	7.5	197
252	Sema4D induces angiogenesis through Met recruitment by Plexin B1. <i>Blood</i> , 2005 , 105, 4321-9	2.2	194

251	Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 7644-8	11.5	184
250	Overexpression of the RON gene in human breast carcinoma. <i>Oncogene</i> , 1998 , 16, 2927-33	9.2	172
249	Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. <i>British Journal of Cancer</i> , 1993 , 68, 746-50	8.7	165
248	A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation. <i>Journal of Cell Biology</i> , 1997 , 137, 1057-68	7.3	156
247	MicroRNAs impair MET-mediated invasive growth. <i>Cancer Research</i> , 2008 , 68, 10128-36	10.1	156
246	A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 674-8	11.5	153
245	Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. <i>Nature Reviews Cancer</i> , 2018 , 18, 341-358	31.3	152
244	Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. <i>Clinical Cancer Research</i> , 2012 , 18, 2515-25	12.9	152
243	Interplay between scatter factor receptors and B plexins controls invasive growth. <i>Oncogene</i> , 2004 , 23, 5131-7	9.2	151
242	Series Introduction: Invasive growth: from development to metastasis. <i>Journal of Clinical Investigation</i> , 2002 , 109, 857-862	15.9	148
241	Tyrosine kinase signal specificity: lessons from the HGF receptor. <i>Trends in Biochemical Sciences</i> , 2003 , 28, 527-33	10.3	146
240	Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. <i>Oncogene</i> , 2000 , 19, 1509-18	9.2	145
239	MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. <i>Cancer Research</i> , 2010 , 70, 7580-90	10.1	144
238	Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 649-53	11.5	142
237	Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. <i>EMBO Journal</i> , 1997 , 16, 495-503	13	140
236	The transmembrane protein Off-track associates with Plexins and functions downstream of Semaphorin signaling during axon guidance. <i>Neuron</i> , 2001 , 32, 53-62	13.9	140
235	Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 5090-5	11.5	137
234	To move or not to move? Semaphorin signalling in cell migration. <i>EMBO Reports</i> , 2004 , 5, 356-61	6.5	132

233	HGF: a multifunctional growth factor controlling cell scattering. <i>International Journal of Biochemistry and Cell Biology</i> , 1999 , 31, 1357-62	5.6	132
232	Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. <i>Oncogene</i> , 1997 , 14, 2417-23	9.2	130
231	Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. <i>Oncogene</i> , 1999 , 18, 5221-31	9.2	129
230	Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. <i>Journal of Clinical Investigation</i> , 2010 , 120, 2684-98	15.9	123
229	Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility. <i>Journal of Biological Chemistry</i> , 1996 , 271, 14119-23	5.4	121
228	Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. <i>Journal of Cell Biology</i> , 1994 , 127, 1743-54	7.3	121
227	Hepatocyte growth factor and its receptor are required for malaria infection. <i>Nature Medicine</i> , 2003 , 9, 1363-9	50.5	119
226	Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. <i>Oncogene</i> , 1997 , 15, 3103-11	9.2	116
225	Plexin-B3 is a functional receptor for semaphorin 5A. <i>EMBO Reports</i> , 2004 , 5, 710-4	6.5	116
224	Silencing the MET oncogene leads to regression of experimental tumors and metastases. <i>Oncogene</i> , 2008 , 27, 684-93	9.2	113
223	Overexpression of the met/HGF receptor in renal cell carcinomas. <i>International Journal of Cancer</i> , 1996 , 69, 212-7	7.5	112
222	The Met pathway: master switch and drug target in cancer progression. <i>FASEB Journal</i> , 2006 , 20, 1611-21	6.9	110
221	Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. <i>Cancer Research</i> , 2011 , 71, 3132-41	10.1	108
220	MET overexpression turns human primary osteoblasts into osteosarcomas. <i>Cancer Research</i> , 2006 , 66, 4750-7	10.1	106
219	The MET oncogene is a functional marker of a glioblastoma stem cell subtype. <i>Cancer Research</i> , 2012 , 72, 4537-50	10.1	104
218	MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 737-47	12.9	104
217	MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. <i>Cancer Research</i> , 2014 , 74, 1857-69	10.1	103
216	Hepatocyte growth factor is a regulator of monocyte-macrophage function. <i>Journal of Immunology</i> , 2001 , 166, 1241-7	5.3	102

215	Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. <i>Clinical Cancer Research</i> , 2011 , 17, 3146-56	12.9	101
214	Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. <i>Journal of Cell Biology</i> , 2006 , 175, 993-1003	7.3	101
213	TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. <i>Oncogene</i> , 2005 , 24, 3002-10	9.2	101
212	Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 14240-5	11.5	100
211	Scatter factors and invasive growth. <i>Seminars in Cancer Biology</i> , 2001 , 11, 153-65	12.7	100
210	Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. <i>Cancer Research</i> , 2005 , 65, 6167-77	10.1	98
209	A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. <i>Oncogene</i> , 2007 , 26, 1078-87	9.2	97
208	The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. <i>Experimental Cell Research</i> , 2003 , 288, 382-9	4.2	97
207	Cleavage of a 135 kD cell surface glycoprotein correlates with loss of fibroblast adhesion to fibronectin. <i>Experimental Cell Research</i> , 1985 , 156, 182-90	4.2	96
206	Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors. <i>Cytokine and Growth Factor Reviews</i> , 1997 , 8, 129-42	17.9	95
205	A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. <i>Journal of Biological Chemistry</i> , 2008 , 283, 21267-77	5.4	95
204	Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. <i>Journal of Biological Chemistry</i> , 2004 , 279, 28970-8	5.4	93
203	ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	91
202	Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. <i>Cancer Research</i> , 2004 , 64, 5154-61	10.1	89
201	HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. <i>FASEB Journal</i> , 2000 , 14, 1629-1640	0.9	88
200	Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 14379-83	11.5	86
199	p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. <i>Journal of Cell Science</i> , 2005 , 118, 4689-700	5.3	84
198	Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. <i>Molecular Cancer</i> , 2010 , 9, 121	42.1	83

197	Apoptosis enhancement by the HIV-1 Nef protein. <i>Journal of Immunology</i> , 2001 , 166, 81-8	5.3	83
196	A point mutation in the MET oncogene abrogates metastasis without affecting transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 13868-72	11.5	82
195	Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. <i>Cancer Research</i> , 2002 , 62, 7025-30	10.1	81
194	Quantitative PET imaging of Met-expressing human cancer xenografts with ⁸⁹ Zr-labelled monoclonal antibody DN30. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35, 1857-67	8.8	80
193	IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. <i>Science Translational Medicine</i> , 2015 , 7, 272ra12	17.5	79
192	The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. <i>Journal of Experimental Medicine</i> , 2008 , 205, 1155-71	16.6	79
191	An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. <i>Journal of Clinical Investigation</i> , 2004 , 114, 1418-32	15.9	79
190	In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995 , 15, 1857-65	9.4	78
189	Sema3E/plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. <i>Journal of Clinical Investigation</i> , 2013 , 123, 5411-5411	15.9	78
188	Only a subset of Met-activated pathways are required to sustain oncogene addiction. <i>Science Signaling</i> , 2009 , 2, ra80	8.8	76
187	Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. <i>Oncogene</i> , 2009 , 28, 1421-31	9.2	75
186	Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Annals of Oncology</i> , 2008 , 19, 1605-12	10.3	74
185	Interactions between scatter factors and their receptors: hints for therapeutic applications. <i>FASEB Journal</i> , 1998 , 12, 1267-80	0.9	72
184	Expression of Met protein in thyroid tumours. <i>Journal of Pathology</i> , 1996 , 180, 266-70	9.4	72
183	Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. <i>International Journal of Cancer</i> , 1999 , 82, 640-3	7.5	70
182	S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1749-62	6.1	69
181	Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. <i>Oncogene</i> , 1999 , 18, 1139-46	9.2	69
180	HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. <i>FASEB Journal</i> , 2000 , 14, 1629-40	0.9	68

179	Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. <i>Journal of Biological Chemistry</i> , 2010 , 285, 36149-57	5.4	67
178	Immunohistochemistry with antibodies to hepatocyte growth factor and its receptor protein (c-MET) in human brain tissues. <i>Brain Research</i> , 1994 , 637, 308-12	3.7	66
177	Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. <i>Cancer Research</i> , 2005 , 65, 10674-9	10.1	65
176	Invasive growth: from development to metastasis. <i>Journal of Clinical Investigation</i> , 2002 , 109, 857-62	15.9	65
175	The HGF receptor family: unconventional signal transducers for invasive cell growth. <i>Genes To Cells</i> , 1996 , 1, 347-54	2.3	62
174	Activation of RAS family members confers resistance to ROS1 targeting drugs. <i>Oncotarget</i> , 2015 , 6, 5182-34	3.4	62
173	Ron kinase transphosphorylation sustains MET oncogene addiction. <i>Cancer Research</i> , 2011 , 71, 1945-55	10.1	61
172	Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. <i>Cancer Genetics and Cytogenetics</i> , 1992 , 64, 170-3		61
171	A 135,000 molecular weight plasma membrane glycoprotein involved in fibronectin-mediated cell adhesion. Immunofluorescence localization in normal and RSV-transformed fibroblasts. <i>Experimental Cell Research</i> , 1986 , 163, 47-62	4.2	61
170	Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesis. <i>BMC Developmental Biology</i> , 2007 , 7, 55	3.1	60
169	Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid. <i>Endocrine Pathology</i> , 2000 , 11, 19-30	4.2	60
168	A gene trap vector system for identifying transcriptionally responsive genes. <i>Nature Biotechnology</i> , 2001 , 19, 579-82	44.5	59
167	Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2322-8	5.6	58
166	Functional regulation of semaphorin receptors by proprotein convertases. <i>Journal of Biological Chemistry</i> , 2003 , 278, 10094-101	5.4	58
165	Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 251-61	35.1	57
164	MET mutations in cancers of unknown primary origin (CUPs). <i>Human Mutation</i> , 2011 , 32, 44-50	4.7	57
163	The Met oncogene and basal-like breast cancer: another culprit to watch out for?. <i>Breast Cancer Research</i> , 2010 , 12, 208	8.3	56
162	Genetic link between cancer and thrombosis. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4827-33	2.2	55

161	Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. <i>Current Drug Targets</i> , 2001 , 2, 41-55	3	55
160	Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth. <i>Experimental Cell Research</i> , 1999 , 253, 88-99	4.2	55
159	Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. <i>International Journal of Cancer</i> , 2000 , 89, 286-292	7.5	54
158	Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. <i>Journal of Endocrinological Investigation</i> , 1995 , 18, 134-9	5.2	54
157	MET inhibition overcomes radiation resistance of glioblastoma stem-like cells. <i>EMBO Molecular Medicine</i> , 2016 , 8, 550-68	12	54
156	Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. <i>Oncogene</i> , 1999 , 18, 4275-81	9.2	52
155	Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. <i>Journal of Clinical Investigation</i> , 2009 , 119, 865-75	15.9	52
154	Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid Carcinomas with High Risk of Distant Metastases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2322-2328	5.6	52
153	A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. <i>Journal of Biological Chemistry</i> , 2010 , 285, 26335-40	5.4	51
152	Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy. <i>Cell Death and Disease</i> , 2014 , 5, e1185	9.8	50
151	Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. <i>Cancer Research</i> , 2014 , 74, 6598-609	10.1	50
150	A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. <i>Journal of Biological Chemistry</i> , 1999 , 274, 29274-81	5.4	50
149	Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. <i>Oncogene</i> , 2013 , 32, 1428-40	9.2	49
148	The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis. <i>Molecular Biology of the Cell</i> , 2009 , 20, 642-57	3.5	49
147	Negative feedback regulation of Met-dependent invasive growth by Notch. <i>Molecular and Cellular Biology</i> , 2005 , 25, 3982-96	4.8	47
146	PDGF-induced receptor phosphorylation and phosphoinositide hydrolysis are unaffected by protein kinase C activation in mouse Swiss 3T3 and human skin fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 1986 , 137, 343-50	3.4	47
145	In vivo phosphorylation and dephosphorylation of the platelet-derived growth factor receptor studied by immunoblot analysis with phosphotyrosine antibodies. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1986 , 881, 54-61	4	47
144	The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. <i>Cancer Research</i> , 2013 , 73, 3193-9	10.1	46

143	Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2. <i>Oncogene</i> , 1997 , 14, 705-11	9.2	46
142	The HIV-1 nef protein interferes with phosphatidylinositol 3-kinase activation 1. <i>Journal of Biological Chemistry</i> , 1996 , 271, 6590-3	5.4	45
141	Bombesin stimulation of c-fos and c-myc gene expression in cultures of Swiss 3T3 cells. <i>Experimental Cell Research</i> , 1986 , 167, 276-80	4.2	45
140	Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. <i>Cancer Research</i> , 2004 , 64, 1744-50	10.1	44
139	Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. <i>Journal of Biotechnology</i> , 1994 , 37, 109-22	3.7	42
138	The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. <i>Journal of Biological Chemistry</i> , 2010 , 285, 38756-64	5.4	41
137	Targeting the MET oncogene in cancer and metastases. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1381-94	5.9	41
136	Two dimensional distribution of concanavalin-A receptor molecules on fibroblast and lymphocyte plasma membranes. <i>FEBS Letters</i> , 1972 , 27, 256-8	3.8	41
135	Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. <i>Clinical and Experimental Metastasis</i> , 2011 , 28, 793-802	4.7	40
134	Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling. <i>Oncogene</i> , 2001 , 20, 156-66	9.2	39
133	p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. <i>International Journal of Cancer</i> , 2006 , 118, 2981-90	7.5	37
132	Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity. <i>Journal of Biological Chemistry</i> , 2003 , 278, 29352-8	5.4	37
131	Inhibition of Src impairs the growth of met-addicted gastric tumors. <i>Clinical Cancer Research</i> , 2010 , 16, 3933-43	12.9	36
130	A functional role for hemostasis in early cancer development. <i>Cancer Research</i> , 2005 , 65, 8579-82	10.1	36
129	Control of invasive growth by the HGF receptor family. <i>Journal of Cellular Physiology</i> , 1997 , 173, 183-6	7	35
128	Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. <i>Journal of Pathology</i> , 1998 , 186, 287-91	9.4	35
127	Genetic targeting of the kinase activity of the Met receptor in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 11412-7	11.5	35
126	The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. <i>International Journal of Cancer</i> , 2014 , 135, 2305-16	7.5	34

125	Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. <i>Human Mutation</i> , 2009 , 30, 1167-74	4.7	34
124	Plexins, semaphorins, and scatter factor receptors: a common root for cell guidance signals?. <i>IUBMB Life</i> , 1999 , 48, 477-82	4.7	34
123	Targeting the oncogenic Met receptor by antibodies and gene therapy. <i>Oncogene</i> , 2015 , 34, 1883-9	9.2	33
122	TNF- α promotes invasive growth through the MET signaling pathway. <i>Molecular Oncology</i> , 2015 , 9, 377-88	7.9	33
121	Immunological detection of proteins phosphorylated at tyrosine in cells stimulated by growth factors or transformed by retroviral-oncogene-coded tyrosine kinases. <i>FEBS Journal</i> , 1986 , 158, 383-91		33
120	Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell lung carcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988 , 85, 2166-70	11.5	33
119	"Active" cancer immunotherapy by anti-Met antibody gene transfer. <i>Cancer Research</i> , 2008 , 68, 9176-83	10.1	32
118	Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. <i>International Journal of Cancer</i> , 1996 , 65, 168-72	7.5	32
117	MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure. <i>Current Opinion in Cell Biology</i> , 2014 , 31, 98-105	9	31
116	Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis. <i>PLoS ONE</i> , 2008 , 3, e3223	3.7	31
115	Invasive growth: a genetic program. <i>International Journal of Developmental Biology</i> , 2004 , 48, 451-6	1.9	31
114	Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. <i>Hepatology</i> , 1995 , 21, 1543-1546	11.2	31
113	Vanadate-treated baby hamster kidney fibroblasts show cytoskeleton and adhesion patterns similar to their Rous sarcoma virus-transformed counterparts. <i>Journal of Cellular Biochemistry</i> , 1988 , 37, 151-9	4.7	31
112	Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor. <i>Stem Cells</i> , 2017 , 35, 2218-2228	5.8	30
111	Plexins, Semaphorins, and Scatter Factor Receptors: A Common Root for Cell Guidance Signals?. <i>IUBMB Life</i> , 1999 , 48, 477-482	4.7	30
110	MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. <i>Cancer Research</i> , 2014 , 74, 3647-51	10.1	28
109	Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor. <i>Journal of Biological Chemistry</i> , 2001 , 276, 46632-8	5.4	28
108	Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. <i>Biochemical Journal</i> , 1998 , 336 (Pt 1), 235-9	3.8	28

107	Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid. <i>Journal of Pathology</i> , 1999 , 189, 570-5	9.4	27
106	Met inhibition revokes IFN γ induction of PD-1 ligands in MET-amplified tumours. <i>British Journal of Cancer</i> , 2019 , 120, 527-536	8.7	26
105	Met-driven invasive growth involves transcriptional regulation of Arhgap12. <i>Oncogene</i> , 2008 , 27, 5590-8	9.2	26
104	Feline STK gene expression in mammary carcinomas. <i>Oncogene</i> , 2002 , 21, 1785-90	9.2	26
103	Affinity chromatography purification of erythrocyte membrane proteins after selective labeling with trinitrobenzene sodium sulfonate. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1973 , 311, 214-21	3.8	26
102	Solubilization of the receptor for the neuropeptide gastrin-releasing peptide (bombesin) with functional ligand binding properties. <i>Biochemistry</i> , 1990 , 29, 5153-60	3.2	25
101	Identification of a 58,000 daltons phosphoprotein with tyrosine protein kinase activity in a murine lymphoma cell line. <i>Biochemical and Biophysical Research Communications</i> , 1984 , 122, 563-70	3.4	25
100	Immunofluorescence localization of phosphotyrosine containing proteins in RSV-transformed mouse fibroblasts. <i>Experimental Cell Research</i> , 1984 , 154, 112-24	4.2	25
99	Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. <i>Oncogene</i> , 2017 , 36, 1200-1210	9.2	24
98	Macrophage stimulating protein is a novel neurotrophic factor. <i>Molecular Biology of the Cell</i> , 2001 , 12, 1341-52	3.5	24
97	Antigenic and immunogenic properties of membrane proteins solubilized by sodium desoxycholate, papain digestion or high ionic strength. <i>Immunochemistry</i> , 1975 , 12, 9-17		24
96	An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. <i>Nature Biotechnology</i> , 2002 , 20, 488-95	44.5	22
95	Regional mapping of the human hepatocyte growth factor (HGF)-scatter factor gene to chromosome 7q21.1. <i>Genomics</i> , 1992 , 13, 912-4	4.3	22
94	Lipid characteristics of RSV-transformed Balb/c 3T3 cell lines with different spontaneous metastatic potentials. <i>Lipids</i> , 1989 , 24, 685-90	1.6	21
93	C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. <i>Oncotarget</i> , 2016 , 7, 45525-45537	3.3	21
92	Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. <i>Oncogene</i> , 2010 , 29, 5286-98	9.2	20
91	"Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1997 , 1333, M41-51	11.2	20
90	Only a subset of Met-activated pathways are required to sustain oncogene addiction. <i>Science Signaling</i> , 2009 , 2, er11	8.8	19

89	A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy. <i>Clinical Cancer Research</i> , 2018 , 24, 807-820	12.9	18
88	Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals. <i>BMC Biology</i> , 2016 , 14, 5	7.3	18
87	MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. <i>British Journal of Haematology</i> , 2014 , 164, 841-50	4.5	18
86	A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. <i>International Journal of Cancer</i> , 2012 , 130, 1357-66	7.5	17
85	A comparative study of SV40-transformed fibroblast plasma membrane proteins labelled by enzymatic iodination or with trinitrobenzene sulfonate. <i>FEBS Letters</i> , 1974 , 47, 107-12	3.8	17
84	A solid-state competitive binding radioimmunoassay for measurement of antigens solubilized from membranes. <i>Journal of Immunological Methods</i> , 1976 , 9, 267-72	2.5	17
83	Proteins phosphorylated on tyrosine as markers of human tumor cell lines. <i>International Journal of Cancer</i> , 1987 , 39, 482-7	7.5	16
82	Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , 1988 , 27, 233-40	7.4	16
81	Metastatic clones selected from an RSV-induced mouse sarcoma share a common marker chromosome. <i>International Journal of Cancer</i> , 1983 , 31, 455-61	7.5	16
80	Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors. <i>Oncotarget</i> , 2017 , 8, 38193-38213	3.3	16
79	Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody. <i>Cancer Research</i> , 2016 , 76, 5019-29	10.1	16
78	Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. <i>Molecular Oncology</i> , 2015 , 9, 1760-72	7.9	15
77	C-met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells. <i>Clinical and Experimental Metastasis</i> , 1998 , 16, 253-65	4.7	15
76	Studies on the outer surface of normal and RSV-transformed BHK fibroblast plasma membrane. <i>Experimental Cell Research</i> , 1975 , 93, 402-10	4.2	15
75	Growth of syngeneic tumours in unimmunized newborn and adult hosts. <i>British Journal of Cancer</i> , 1973 , 27, 120-7	8.7	15
74	Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. <i>Molecular Oncology</i> , 2014 , 8, 1561-74	7.9	14
73	Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. <i>Hepatology</i> , 2008 , 47, 2010-25	11.2	14
72	Protein tyrosine kinases associated with human malignancies. <i>Annals of the New York Academy of Sciences</i> , 1987 , 511, 256-61	6.5	14

71	Binding of serum polypeptides to the plasma membrane outer surface. <i>FEBS Letters</i> , 1976 , 67, 364-7	3.8	14
70	Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer. <i>Human Mutation</i> , 2018 , 39, 371-377	4.7	14
69	MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	14
68	Role of heterochromatin variation in the instability of a marker chromosome during tumor progression. <i>Cancer Genetics and Cytogenetics</i> , 1985 , 15, 283-91		13
67	Identification and partial characterization of five major membrane glycoproteins of BHK fibroblasts. <i>Journal of Membrane Biology</i> , 1980 , 53, 55-61	2.3	13
66	A differentiation switch for genetically modified hepatocytes. <i>FASEB Journal</i> , 2002 , 16, 120-2	0.9	12
65	Evidence for autocrine activation of a tyrosine kinase in a human gastric carcinoma cell line. <i>Journal of Cellular Biochemistry</i> , 1988 , 38, 229-36	4.7	12
64	The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers. <i>International Journal of Cancer</i> , 2018 , 143, 2838-2848	7.5	11
63	Regulation by EGF is maintained in an overexpressed chimeric EGFR/neu receptor tyrosine kinase. <i>Journal of Cellular Biochemistry</i> , 1990 , 42, 123-33	4.7	11
62	Characterization of T lymphocytes mediating in vivo protection against RSV-induced murine sarcomas. <i>International Journal of Cancer</i> , 1983 , 31, 757-64	7.5	11
61	Mouse fibroblasts transformed by Rous sarcoma virus express a virus-specific non-virion transplantation antigen. <i>International Journal of Cancer</i> , 1981 , 27, 797-805	7.5	11
60	A virus-induced non-virion antigen specific for transformation at the surface of RSV-transformed fibroblasts. <i>Nature</i> , 1978 , 273, 381-3	50.4	11
59	Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 10058-10063	11.5	11
58	Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice. <i>Cancer Immunology, Immunotherapy</i> , 1989 , 29, 185-92	7.4	10
57	Protein phosphorylation at tyrosine residues in v-abl transformed mouse lymphocytes and fibroblasts. <i>International Journal of Cancer</i> , 1986 , 37, 623-8	7.5	10
56	Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody. <i>Molecular Oncology</i> , 2016 , 10, 938-48	7.9	10
55	HGF and MET: From Brain Development to Neurological Disorders. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 683609	5.7	9
54	Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy. <i>International Journal of Cancer</i> , 2018 , 143, 1774-1785	7.5	8

53	Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. <i>Journal of Molecular Medicine</i> , 2014 , 92, 65-76	5.5	8
52	Biochemical and immunological properties of the human carcinoma antigen CAR-5 defined by the monoclonal antibody BD-5. <i>International Journal of Cancer</i> , 1989 , 44, 67-74	7.5	8
51	Organization of cytoskeleton and fibronectin matrix in Rous sarcoma virus (RSV)-transformed fibroblast lines with different metastatic potential. <i>European Journal of Cancer & Clinical Oncology</i> , 1985 , 21, 85-96		8
50	Effect of solubilized membrane antigens and tumour bearer serum on tumour growth in syngeneic hosts. <i>British Journal of Cancer</i> , 1974 , 30, 365-9	8.7	8
49	Plasma membrane proteins exposed on the outer surface of control and Rous sarcoma virus-transformed hamster fibroblasts. <i>Experimental Cell Research</i> , 1977 , 110, 143-52	4.2	8
48	Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report. <i>EMBO Molecular Medicine</i> , 2020 , 12, e11756	12	8
47	Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes. <i>British Journal of Cancer</i> , 1976 , 34, 233-8	8.7	7
46	Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. <i>Journal of Molecular and Cellular Cardiology</i> , 2016 , 93, 84-97	5.8	6
45	An Q1-cell trial to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. <i>Molecular Oncology</i> , 2014 , 8, 378-88	7.9	6
44	Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation. <i>Journal of Cellular Biochemistry</i> , 1991 , 45, 69-81	4.7	6
43	Cell surface changes during muscle differentiation in vitro: a study with the probe 2,4,6-trinitrobenzene sulphonate. <i>Cell Differentiation</i> , 1979 , 8, 1-9		6
42	Interaction between cellular and viral genes in the expression of the RSV-induced transformation-specific cell-surface antigen VCSA. <i>International Journal of Cancer</i> , 1980 , 25, 355-62	7.5	6
41	Dissection of the antigenic determinants expressed on the cell surface of RSV-transformed fibroblasts by monoclonal antibodies. <i>International Journal of Cancer</i> , 1982 , 29, 477-81	7.5	6
40	Neuraminidase sensitive antigenic determinants of plasma cell tumor membrane glycoproteins. <i>FEBS Letters</i> , 1975 , 51, 351-4	3.8	6
39	Plasma-cell and tumor-associated membrane antigens of mouse plasmacytoma MOPC-315 and MOPC-460. <i>International Journal of Cancer</i> , 1973 , 12, 613-25	7.5	6
38	Scatter factor receptors are key players in a unique multistep program leading to invasive growth. <i>Novartis Foundation Symposium</i> , 1997 , 212, 133-44; discussion 144-7		6
37	Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness. <i>Oncogene</i> , 2001 , 20, 5493-502	9.2	5
36	Ligand-independent tyrosine phosphorylation of the receptor encoded by the c-neu oncogene. <i>Growth Factors</i> , 1991 , 5, 233-42	1.6	5

35	Expression of the monoclonal antibody-defined CAR-3 epitope on neoplastic and preneoplastic lesions of the colon mucosa. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 923-32		5
34	Phosphoinositides are not phosphorylated by the very active tyrosine protein kinase from the murine lymphoma LSTRA. <i>Biochemical and Biophysical Research Communications</i> , 1985 , 132, 481-9	3.4	5
33	Tumor-specific and tumor-associated membrane antigens of Rous sarcoma virus transformed hamster fibroblasts. <i>International Journal of Cancer</i> , 1978 , 22, 55-62	7.5	5
32	Immunochemical purification of probe-labeled plasma membrane proteins: an approach to the molecular anatomy of the cell surface. <i>Journal of Supramolecular Structure</i> , 1978 , 8, 39-49		5
31	MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin. <i>EBioMedicine</i> , 2017 , 24, 34-42	8.8	4
30	The Fathers of Italian Histology. <i>European Journal of Histochemistry</i> , 2009 , 51, 1	2.1	4
29	Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions*1. <i>Hepatology</i> , 1995 , 21, 1543-1546	11.2	4
28	Kinetics of tyrosine phosphorylation and internalization of human EGF receptors overexpressed in NIH 3T3 fibroblasts. <i>Experimental Cell Research</i> , 1990 , 191, 323-7	4.2	4
27	A tyrosine protein kinase activated by bombesin in normal fibroblasts and small cell carcinomas. <i>Annals of the New York Academy of Sciences</i> , 1988 , 547, 293-302	6.5	4
26	Involvement of sialic acids in the immunological specificity of plasma membrane glycoproteins. <i>Immunochemistry</i> , 1976 , 13, 97-102		4
25	Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. <i>Nature Communications</i> , 2021 , 12, 2498	17.4	4
24	Characterization of the detergent solubilized receptor for gastrin-releasing peptide. <i>Peptides</i> , 1990 , 11, 737-45	3.8	3
23	Monoclonal antibodies to the collagen binding domain of human plasma fibronectin. <i>Pathobiology</i> , 1984 , 52, 225-36	3.6	3
22	Effect of the growth conditions on the expression of cell-surface-associated platelet-derived growth factor receptors in mouse fibroblasts. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 1988 , 971, 351-357	4.6	2
21	ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. <i>Cell Reports</i> , 2021 , 36, 109455	10.6	2
20	A receptor-antibody hybrid hampering MET-driven metastatic spread. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 32	12.8	2
19	The hepatocyte growth factor receptor (MET): An unconventional transducer of mitogenic and motogenic signals. <i>Growth Factors and Cytokines in Health and Disease</i> , 1996 , 1, 465-490		1
18	Interaction of fibroblasts, hemopoietic cells and platelets with extracellular matrix: characterization and role of a common cell surface glycoprotein. <i>Annals of the New York Academy of Sciences</i> , 1987 , 511, 65-76	6.5	1

17	The tyrosine kinase associated with the bombesin receptor complex: Evidences for autocrine activation in small cell lung carcinomas. <i>Lung Cancer</i> , 1988 , 4, 190-195	5.9	1
16	Antigen-dependent mast cell differentiation in vitro. <i>Experimental Cell Research</i> , 1972 , 72, 404-8	4.2	1
15	Oncogenes, Cancer and Hemostasis 2007 , 1-15		1
14	Structure and functions of the HGF receptor (c-Met) 1995 , 51-70		1
13	MET Exon 14 Skipping: A Case Study for the Detection of Genetic Variants in Cancer Driver Genes by Deep Learning. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
12	Factor XII protects neurons from apoptosis by epidermal and hepatocyte growth factor receptor-dependent mechanisms. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2235-2247	15.4	1
11	Discovery and Function of the HGF/MET and the MSP/RON Kinase Signaling Pathways in Cancer 2018 , 1-43		1
10	hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of MET-addicted cancers.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 112	12.8	0
9	MET14 promotes a ligand-dependent, AKT-driven invasive growth. <i>Life Science Alliance</i> , 2022 , 5, e202201409	14.9	0
8	Growth factor receptors and class 1 oncogenes in cancer. <i>Animal Genetics</i> , 1989 , 20, 348-50	2.5	
7	Scatter Factors in Tumor Progression 2006 , 111-142		
6	Hepatocyte Growth Factor/Scatter Factor Receptor 2004 , 367-371		
5	Effect of the growth conditions on the expression of cell-surface-associated platelet-derived growth factor receptors in mouse fibroblasts. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1988 , 971, 351-7	4.9	
4	Morphological and biochemical changes of rat prostate organ cultures and their reaction to prostate extracts. <i>Life Sciences</i> , 1971 , 10, 325-31	6.8	
3	Detection of deregulated tyrosine-kinases in experimental and human metastatic tumors. <i>Advances in Experimental Medicine and Biology</i> , 1988 , 233, 303-8	3.6	
2	The Receptor for the Hepatocyte Growth Factor-Scatter Factor: Ligand-Dependent and Phosphorylation-Dependent Regulation of Kinase Activity 1992 , 301-310		
1	Control of Invasive Cell Growth by the Met Family Oncogenes 1996 , 23-43		